ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced the closure of a EUR77.8 million private placement. The private placement allowed ThromboGenics to place 3,244,675 new shares with domestic and international investors at a price of EUR24 per share, representing a 3.5% discount on the company’s previous closing price. The placement brings the total number of shares after issuance to 35,691,432, listed on NYSE Euronext Brussels.